Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung Thi Le, Jennifer N. Durham, Kellie Nicole Smith et al. · Science · 2017
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor-1 (PD-1). We have now expanded this study to evaluate the efficacy of PD-1 blockade in patients with advanced mismatch repair-deficient cancers across 12 different tumor types. Objective radiographic responses were observed in 53% of patients, and complete responses were achieved in 21% of patients. Responses were durable, with median progression-free survival and overall survival still not reached. Functional analysis in a responding patient demonstrated rapid in vivo expansion of neoantigen-specific T cell clones that were reactive to mutant neopeptides found in the tumor. These data support the hypothesis that the large proportion of mutant neoantigens in mismatch repair-deficient cancers make them sensitive to immune checkpoint blockade, regardless of the cancers' tissue of origin.
Cited by 6,607 works. doi:10.1126/science.aan6733
Authors
- Dung Thi Le
- Jennifer N. Durham
- Kellie Nicole Smith
- Hao Wang
- Bjarne R. Bartlett
- Laveet K. Aulakh
- Steve Lu
- Holly Kemberling
- Cara Wilt
- Brandon S. Luber
- Fay Wong
- Nilofer Saba Azad
- Agnieszka A. Rucki
- Dan A. Laheru
- Ross C. Donehower
- Atif Zaheer
- George Albert Fisher
- Todd S. Crocenzi
- James J. Lee
- Tim F. Greten
References
- A general method applicable to the search for similarities in the amino acid sequence of two proteins
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Genetic instabilities in human cancers
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab